Trials
4 active
10 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Idiopathic Pulmonary Fibrosis (2 trials), Refractory Chronic Cough
- Main trialPhase 3
- “The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with IPF.”In the company’s words, NCT07868419 on ClinicalTrials.gov
- Other names
- Nalbuphine · Nalbuphine Extended Release
Other drugs for Idiopathic Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
Coming up4
- 30 NovPhase 1 trial completes · ClinicalTrials.gov
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 18 NovNew trial: none to Phase 1 · ClinicalTrials.gov NCT07946575
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets | |
| Phase 3Recruiting | Jun 2028 | Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets | |
| Phase 2Recruiting | Sep 2027 | The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) | |
| Phase 1Recruiting | 30 Nov 2026 | A Study of the Potential Pharmacokinetic Interaction Between Quinidine Sulfate and Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants | |
| Phase 2Completed | 27 May 2022 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | |
| Phase 2Completed | 6 Jan 2025 | Refractory Chronic Cough Improvement Via NAL ER (RIVER) | |
| Phase 2Completed | 24 Apr 2025 | Cough Reduction in IPF With Nalbuphine ER | |
| Phase 1Completed | 12 Sep 2025 | A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants | |
| Phase 1Completed | 11 May 2026 | A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants | |
| Phase 1Completed | 30 Jun 2026 | NAL ER IPF Respiratory Function and Safety Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026